Abstract
The following corrections applies to “The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO)” by K Murakami, J Wada, D Ogawa, CS Horiguchi, T Miyoshi, M Sasaki, HA Uchida, Y Nakamura and H Makino. Diabetes and Vascular Disease Research 2013; 10(1): 93–96. DOI: 10.1177/1479164112444640.
The following conflicts of interest were omitted from the published article
DO and CSH belong to Department of Diabetic Nephropathy endowed by Astellas and Boehringer Ingelheim. JW is a consultant for Boehringer Ingelheim, receives speaker honoraria from Astellas, Boehringer Ingelheim, Daiichi Sankyo, Dainippon Sumitomo, Eli Lilly, Kyowa Hakko Kirin, MSD, Novartis, Novo Nordisk, Sanofi, Shionogi, Takeda, Tanabe Mitsubishi, and grant support from Mochida. HM is a consultant for AbbVie and Astellas, receives speaker honoraria from Astellas, MSD, Takeda, and Tanabe Mitsubishi, and receives grant support from Astellas, Daiichi Sankyo, Dainippon Sumitomo, MSD, Novo Nodisk and Takeda.
The authors apologize for this omission.